Investigational drug · Phase 2
QLC5513
Not approved by FDA. In 1 industry-sponsored Phase 2 or 3 trial that is active or finished in the last two years, most often for Metastatic Solid Tumors.
Phase 2Last checked: Nov 19, 2026Latest source record: Dec 9, 2025 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 2
Industry-sponsored trials
Phase 2 and 3 trials
1
1 still active
All registered trials
2
Any phase or sponsor naming "QLC5513"
First trial start
2025
Dec 30, 2025
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "QLC5513", any sponsor or status.
Conditions studied
As listed on its trial records.
- Metastatic Solid Tumors
Approved drugs for the same conditions: Oncology
Largest trials
Live from ClinicalTrials.gov: studies naming "QLC5513" as an intervention, largest first.
- Study of QLC5513 in Combination With Epalolimab Tovolimab (QL1706) ± Platinum in Patients With Advanced or Metastatic Malignant Solid TumorsPivotal-lookingNot yet recruiting
Qilu Pharmaceutical Co., Ltd.Industry
NCT07272590 · 290 participants (planned) · Start Dec 30, 2025 · Primary completion Jun 2027
Drug: QLC5513 IV infusion; QL1706, IV infusion and 1 more · For: Metastatic Solid Tumors
- QLC5513 Alone or in Combination With QL1706 in Previously Treated Advanced or Metastatic TNBC.Not yet recruiting
Fudan UniversityAcademic, hospital or other
NCT07509515 · 60 participants (planned) · Start Apr 15, 2026 · Primary completion Sep 30, 2027
Drug: QLC5513; QLC5513+QL1706 · For: Triple-negative Breast Cancer (TNBC)
Newest research
PubMed records naming it or its code names, newest first.
No PubMed records name it yet, which is common for early code-named drugs.
Also in development for Metastatic Solid Tumors
- R-DXdDS 6000a, MK-5909Phase 310 trials
Merck & Co. · Fallopian Tube Cancer, Ovarian Cancer, Peritoneal Cancer
- EzabenlimabBI 754091Phase 32 trials
Boehringer Ingelheim · Advanced Cancer, Neoplasm Metastasis, Advanced Tumors
- RMC-6291ElironrasibPhase 23 trials
Revolution Medicines, Inc. · Non-Small Cell Lung Cancer, NSCLC, KRAS, NRAS, HRAS-mutated NSCLC, KRAS G12C-mutated Solid Tumors, Lung Cancer
- AVZO-103Phase 21 trial
Avenzo Therapeutics, Inc. · Solid Tumor Cancer, Locally Advanced, Metastatic Solid Tumors
- AVZO-1418Phase 21 trial
Avenzo Therapeutics, Inc. · Solid Tumor Cancer, Locally Advanced, Metastatic Solid Tumors
- BI 754111Phase 21 trial
Boehringer Ingelheim · Neoplasm Metastasis, Advanced Tumors, Metastatic Solid Tumors
- BI 836880Phase 21 trial
Boehringer Ingelheim · Neoplasm Metastasis, Advanced Tumors, Metastatic Solid Tumors
- BPR-6023021Phase 21 trial
Chengdu Syncor Pharmaceutical Co., Ltd. · Metastatic Solid Tumors
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.